What you will find here
Thymosin Alpha-1 Source Reports Successes and Failures
We tell you what happened to patients without turning the facts into a sales pitch.
Good and bad study results both belong here
You may want the Thymosin Alpha-1 facts without a wall of lab terms. Thymosin Alpha-1 Source tells how study patients fared.
The failed final-stage test, called phase 3, gets the same attention as hopeful liver work. Those patients had sepsis, when the fight against infection turns deadly.
No clinic or pharmacy runs these pages. We don't treat patients, write drug orders, sell medicine, or choose anyone's care.
The word "Source" refers to study papers
Here, "Source" means the papers behind each study claim. It doesn't mean a place that supplies the drug.
We don't sell Thymosin Alpha-1 or arrange prescriptions. We also don't point toward vials offered only for lab work.
The name refers to published research, not a product. This isn't a shopping site.
Each study number links to its paper
Every study figure points to our Thymosin Alpha-1 references. A bracketed number beside a claim takes you straight to its source paper.
We say who entered each study and how they fared. A dose used in research never becomes personal advice here.
User reports stay separate from study findings. When the strongest test finds no benefit, we say that plainly.
The immune drug is not the tissue-repair drug
Similar names lead people to confuse Thymosin Alpha-1 with thymosin beta-4, also called TB-500. The second is studied for tissue repair; the first guides immune cells.
Other drugs also carry the word "thymosin." They aren't the same, and a true fact about one may be false for another.
Compounded thymosin alpha-1 has no FDA approval. Its studies deal with immune care, not muscle growth or sports gains.